1Nozaki K, Shimizu N, Tsukamoto T. Reversibility of Heterotoplc Proliferative Glends in Glandular Stomach of Helicobacter pyloriinfected Monolian Gerbils on Eradication [ J ]. Jpn Cancer Res,2002,93(4) :374 - 381.
2Marchetti M, Arico B, Burroni D, et al. Development of a mouse model of Helicobacter pylori infection that mimics human disease[J]. Science, 1995, 267:1665.
3Ermak TH, Giannascs PJ, Nichois R, et al. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies end is mediated by MHC class Ⅱ - restricted responses[J]. Exp Med, 1998, 188:2277 -22
4Pappo J, Jorrey D, Gastriotta L, et al. Helicobacter pylori infection in immunized mice lacking major histocompatibilit. y complex class Ⅰ and class Ⅱ functions[ J ]. Infect Immun, 1999, 67 (1): 337 -341.
5Melissa D, Timothy T, Harry K, et al. Safety and immunogenicity of phoP/phoQ- deleted Salmonella typhi expressing Helicobaccer pylori urease in adult volunteers [ J ]. Vaccine, 2000, 18:449 -459
6Keenan J, Neal S, Allardyce R, et al. Serum - derived IgG1 - mediated immune exclusion as a mechanism of protection against H.pylori infection[J]. Vaccine, 2002, 20: 2981 - 2988.
7Bumann D, Aksu S, Wendland M, Janek K, et al. Proteome analysis of secreted proteins of the gastric pathogen helicobacter pylori[J]. Infect Immun, 2002, 70 (7) :3396 - 3403.
8Keenan J, Oliaro J, Domigan N, et al. Immune response to an 18 -kilodalton outer membrane antigen identifies lipoprotein 20 as a Helicobacter pylori vaccine candidate[J]. Infect Immun, 2000, 68(6) :3337 - 3343.
9Satin B, Del Giudice G, Della Bianca V, et al. The neutrophil - activating protein(HP - NAP) of Helicobacter pylori is a protective antigen and a major virulence factor[J]. Exp Med, 2000, 191(9):1467 - 1476.
10Ruiz - Bustos E, Sierra - Beltran A, Romero MJ, et al. Protection ot BALB/c mice against experimental Helicobacter pylori infection by oral immunization with H. pyloriheparan sulphate- binding proteins coupled to cholera toxin beta- subunit[J]. Med Microb
二级参考文献5
1徐克强.－[J].国外医学生理、病理与临床分册,1997,17(3):217-220.
2Ausubel FM Brent R.精编分子生物学指南[M].北京:科学出版社,1998.39.
5Robinson K, Chamberlain LM, Lopez MC, et al. Mueosal and cel- lular immune responses elicited by recombinant Lactococcus lactis strains expressing tetanus toxin fragment C [ J ]. Infect Immun, 2004,72(5) :2753 -2761.
6Mierau I,Olieman K,Mond J,et al. Optimization of the Lactococ- cus lactis nisin-controlled gene expression system NICE for indus- trial applications [ J ]. Microbial Cell Factories, 2005,4 ( 1 ) : 16.
7Ribeiro LA, Azevedo V, Le Loir Y, et al. Production and targeting of the Brucella abortus antigen L7/L12 in Lactococcus lactis: a first step towards food-grade live vaccines against brucellosis[ J ]. Appl Environ Microbiol,2002,68 (2) :910 - 916.
8Norton PM, Wells JM, Brown HW, et al. Protection against tetanus toxin in mice nasally immunized with recombinant Lactococcus lactis expressing tetanus toxin fragment C[ J]. Vaccine, 1997,15 (6 -7) :616 -619.
9Chatel JM, Langella P, Adel-Patient K, et al. Induction of mucosal immune response after intranasal or oral inoculation of mice with Lactococcus lactis producing bovine beta-lactoglobulin [ J ]. Clin Diagn Lab Immunol, 2001,8 ( 3 ) :545 - 551.
10Bermudez-Humaran LG,Cortes-Perez NG,Le Loir Y,et al. An in- ducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci [ J ]. J Meal Mierobiol, 2004,53(5) :427 -433.
